Ann: Brain Injury Program GLP Studies Further Update, page-24

not sure who Roch and what they mean to you

However for a 6 million market cap on a drug company that has around 6 million in cash including R&D rebates, drug that targets the source of brain injury exactly like AGN, GLP results that have so far proven its safety and heading into a fully funded Phase 1 study that proves that the drug is safe and the only drug in the world for both traumatic brain injury and stroke together, compared to AGN only completed phase 1 for stroke, the investment is very compelling with a significant upside coming up.

CEO James is hosting a Webinar next week on non dilutive funding after phase 1 completion hopefully you can attend and stop making lies wasting your time trying to troll on a stock you don’t own